Market closed
Shattuck Labs/STTK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Shattuck Labs
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Ticker
STTK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
75
Website
Shattuck Labs Metrics
BasicAdvanced
$60M
Market cap
-
P/E ratio
-$1.83
EPS
1.75
Beta
-
Dividend rate
Price and volume
Market cap
$60M
Beta
1.75
52-week high
$11.76
52-week low
$1.07
Average daily volume
801K
Financial strength
Current ratio
7.615
Quick ratio
7.011
Long term debt to equity
2.687
Total debt to equity
3.452
Management effectiveness
Return on assets (TTM)
-39.74%
Return on equity (TTM)
-68.48%
Valuation
Price to revenue (TTM)
14.272
Price to book
0.54
Price to tangible book (TTM)
0.54
Price to free cash flow (TTM)
-0.93
Growth
Revenue change (TTM)
380.09%
Earnings per share change (TTM)
-15.92%
3-year revenue growth (CAGR)
31.44%
3-year earnings per share growth (CAGR)
0.16%
What the Analysts think about Shattuck Labs
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Shattuck Labs stock.
Shattuck Labs Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Shattuck Labs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Shattuck Labs News
AllArticlesVideos
Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial
Market Watch·1 week ago
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
GlobeNewsWire·1 week ago
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Shattuck Labs stock?
Shattuck Labs (STTK) has a market cap of $60M as of October 10, 2024.
What is the P/E ratio for Shattuck Labs stock?
The price to earnings (P/E) ratio for Shattuck Labs (STTK) stock is 0 as of October 10, 2024.
Does Shattuck Labs stock pay dividends?
No, Shattuck Labs (STTK) stock does not pay dividends to its shareholders as of October 10, 2024.
When is the next Shattuck Labs dividend payment date?
Shattuck Labs (STTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Shattuck Labs?
Shattuck Labs (STTK) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.